Crisis Capital Snapshot: Impact on Private Biotech Financing
This article was originally published in Start Up
Executive SummaryAccording to data from FDC-Windhover's Strategic Transactions, during the five full months since the beginning of the current crisis (September 2008 through January 2009), private biopharma companies raised $1,657 million across 94 deals. In the same time-frame last year that same cohort did 112 transactions and raised $2,187 million. In short, total funding has declined roughly 24% from one period to the next.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.